Patient-Reported Outcome Version of the Common Criteria for Adverse Events

Sponsor
St. Jude Children's Research Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04050072
Collaborator
National Cancer Institute (NCI) (NIH)
165
1
54.5
3

Study Details

Study Description

Brief Summary

Childhood cancer survivors are vulnerable to treatment-related late effects, including physical and psychosocial morbidities, subsequent malignancies, and premature death. Symptom assessment provides a unique insight into survivorship care since symptoms not only indicate the manifestation for the occurrence of chronic health conditions, but also impact quality of life and survival. The National Cancer Institute (NCI) has developed a Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) to assess symptomatic adverse events (AEs) for adult-onset cancer patients who are receiving cancer therapies. However, content-appropriate and clinically validated symptom assessment tools for adult survivors of childhood cancer are not available.

Primary Object 1: Establish content validity for the PRO-CTCAE-SCC

Primary Objective 1A: Conduct a symptom selection process through qualitative research to identify symptomatic AEs for adult survivors of childhood cancer

Primary Objective 1B: Create symptomatic AE items for adult survivors of childhood cancer based on the prevalence and clinical importance ratings on the items

Primary Objective 2: Validate the PRO-CTCAE-SCC using psychometric methods and objective clinical parameters

Primary Objective 2A: Test dimensionality for the PRO-CTCAE-SCC

Primary Objective 2B: Test clinical validity for the PRO-CTCAE-SCC

Primary Objective 2C: Test responsiveness to change for the PRO-CTCAE-SCC

Secondary Objective 1: Increase clinical usefulness of the PRO-CTCAE-SCC

Secondary Objective 2: Establish meaningful cut-points and minimally important differences (MIDs) on symptom burden scores for clinical decision-making

Condition or Disease Intervention/Treatment Phase
  • Other: Childhood Cancer Survivors (CCSS)
  • Other: SJLIFE
  • Other: Community non-cancer control

Detailed Description

We propose to adapt an existing symptomatic adverse event tool, the Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE), to be content appropriate and clinically meaningful for adult survivors of childhood cancer using two well-established childhood cancer survivor cohorts. Psychometric methodologies will be used to validate this tool by incorporating objective clinical anchors collected from medical evaluations. Our symptomatic AE tool has the potential to augment the Children Oncology Group Survivorship Care Guidelines by implementing risk-based symptom screening to track and anticipate adverse health events.

Study Design

Study Type:
Observational
Anticipated Enrollment :
165 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Patient-Reported Outcome Version of the Common Criteria for Adverse Events
Actual Study Start Date :
Dec 16, 2019
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Childhood Cancer Survivors (CCSS)

i. PRO-CTCAE-SCC ii.Quality of life assessment

Other: Childhood Cancer Survivors (CCSS)
To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
Other Names:
  • Quality of life assessment
  • Late medical effects and health care utilization
  • Lifestyle assessment
  • St. Jude Life (SJLIFE)

    i. PRO-CTCAE-SCC ii. Quality of life assessment iii. Comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation

    Other: SJLIFE
    To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.
    Other Names:
  • Quality of life assessment
  • Comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation
  • Community non-cancer control

    i. PRO-CTCAE-SCC ii.Quality of life assessment

    Other: Community non-cancer control
    To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
    Other Names:
  • Quality of life assessment
  • Late medical effects and health care utilization
  • Lifestyle assessment
  • Outcome Measures

    Primary Outcome Measures

    1. PRO-CTCAE-SCC [Years 1-5]

      Conduct a symptom selection process through qualitative research to identify symptomatic AEs for adult survivors of childhood cancer, create symptomatic AE items for adult survivors of childhood cancer based on the prevalence and clinical importance ratings on the items, test dimensionality for the PRO-CTCAE-SCC, test clinical validity for the PRO-CTCAE-SCC and test responsiveness to change for the PRO-CTCAE-SCC.

    Secondary Outcome Measures

    1. Core and Target Scales of the PRO-CTCAE-SCC [Years 4 and 5]

      Develop tailored versions for survivors of different diagnoses exposed to different therapies and establish meaningful cut-points and minimally important differences (MIDs) on symptom burden scores for clinical decision-making.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • or equal to16 years of age at the time of enrollment

    • or equal to 5 years from initial diagnosis of pediatric cancer/malignancy (for CCSS and SJLIFE survivors only) and currently not receiving cancer therapies.

    Exclusion Criteria:
    • Have a known severe neurocognitive impairment, which requires proxies/parents to complete the survey

    • Have < third grade reading level or are not able to communicate in English

    • Unable to use and/or access internet or computer/tablet (for survey only)

    • Unable to communicate and read in English

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 St. Jude Children's Research Hospital Memphis Tennessee United States 38105

    Sponsors and Collaborators

    • St. Jude Children's Research Hospital
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: I-Chang Huang, PhD, St. Jude Children's Research Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    St. Jude Children's Research Hospital
    ClinicalTrials.gov Identifier:
    NCT04050072
    Other Study ID Numbers:
    • PROSYM
    • 1R01CA238368-01A1
    First Posted:
    Aug 8, 2019
    Last Update Posted:
    Oct 11, 2021
    Last Verified:
    Oct 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by St. Jude Children's Research Hospital

    Study Results

    No Results Posted as of Oct 11, 2021